Humana's Coverage Criteria for Onivyde (Irinotecan Liposome) in New Jersey: What Counts as "Medically Necessary"?
Answer Box: Humana Onivyde Coverage in New Jersey
Onivyde (irinotecan liposome) is covered by Humana Medicare Advantage with prior authorization for FDA-approved pancreatic cancer indications. Medical necessity requires: ECOG performance status 0-1, documented diagnosis, and appropriate line of therapy (first-line NALIRIFOX or second-line post-gemcitabine). Fastest approval: Submit complete PA documentation